Siltuximab Biosimilar – Anti-IL6 mAb – Research Grade

General Information on Siltuximab Anti-IL6 Monoclonal Antibody

The Siltuximab antibody is a chimeric mouse/human monoclonal antibody designed to bind human interleukin-6 (IL-6), a soluble glycoprotein involved in pro-inflammatory signaling pathways.

Siltuximab is widely studied in research involving cytokine signaling, immune response regulation and inflammatory mechanisms. IL-6 is one of the major pro-inflammatory cytokines overexpressed in multiple pathological conditions and is produced by several cell types including T cells, B cells, monocytes, fibroblasts and endothelial cells.

By interacting with membrane-bound or soluble IL-6 receptors (IL6R), IL-6 can trigger multiple biological responses such as B-cell proliferation, vascular endothelial growth factor (VEGF) production and immune system dysregulation.

Siltuximab has been investigated in research related to inflammatory diseases, oncology and cytokine-mediated pathways, including studies involving multicentric Castleman disease (MCD), multiple myeloma and immune response dysregulation

Applications

This anti-IL6 monoclonal antibody is suitable for:

• cytokine signaling studies
• ELISA and binding assays
• antibody characterization
• immunology research
• inflammation-related studies
• cell-based assays

This Siltuximab biosimilar anti-IL6 monoclonal antibody is intended for research use only.